The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.

ABSTRACT: The arrival of ipilimumab and vemurafenib has provided oncologists with new choices in a field in which options were slim and the prognosis was grim. Combination therapy may lead to an improved survival benefit.

SUBMITTER: McCain J 

PROVIDER: S-EPMC3628180 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature